{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:13:18Z","timestamp":1793862798397,"version":"4.6.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clinre.2025.102591","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T17:32:32Z","timestamp":1744479152000},"page":"102591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of intravenous vedolizumab treatment in Chinese patients with moderate-to-severe Crohn's disease"],"prefix":"10.1016","volume":"49","author":[{"given":"Minhu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Rossiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayuki","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2025.102591_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/phrs.2021.1603990","article-title":"A review of inflammatory bowel disease: a model of microbial, immune and neuropsychological integration","volume":"42","author":"Tavakoli","year":"2021","journal-title":"Public Health Rev"},{"issue":"9","key":"10.1016\/j.clinre.2025.102591_bib0002","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/ecco-jcc\/jjab029","article-title":"The burden of inflammatory bowel disease in Europe in 2020","volume":"15","author":"Zhao","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"5","key":"10.1016\/j.clinre.2025.102591_bib0003","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/MIB.0000000000001060","article-title":"Patient-reported outcomes of quality of life, functioning, and GI\/psychiatric symptom severity in patients with inflammatory bowel disease (IBD)","volume":"23","author":"IsHak","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clinre.2025.102591_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.714057","article-title":"Depression and anxiety disorders in patients with inflammatory bowel disease","volume":"12","author":"Hu","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.clinre.2025.102591_bib0005","article-title":"Landscape and predictions of inflammatory bowel disease in China: china will enter the Compounding Prevalence stage around 2030","volume":"10","author":"Shao","year":"2022","journal-title":"Front Public Health"},{"issue":"3","key":"10.1016\/j.clinre.2025.102591_bib0006","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/ijerph14030238","article-title":"The disease burden and clinical characteristics of inflammatory bowel disease in the Chinese population: a systematic review and meta-analysis","volume":"14","author":"Li","year":"2017","journal-title":"Int J Environ Res Public Health"},{"issue":"13","key":"10.1016\/j.clinre.2025.102591_bib0007","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1016\/j.cgh.2023.08.013","article-title":"Incidence of inflammatory bowel disease in urban China: a nationwide population-based study","volume":"21","author":"Xu","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2025.102591_bib0008","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10.1016\/j.clinre.2025.102591_bib0009","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"3","key":"10.1016\/j.clinre.2025.102591_bib0010","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clinre.2025.102591_bib0011","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's disease: results from the VISIBLE 2 randomised trial","volume":"16","author":"Vermeire","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"8","key":"10.1016\/j.clinre.2025.102591_bib0012","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ibd.21896","article-title":"Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study","volume":"18","author":"Parikh","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"40","key":"10.1016\/j.clinre.2025.102591_bib0013","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030590","article-title":"Efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials","volume":"101","author":"Qiu","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"13","key":"10.1016\/j.clinre.2025.102591_bib0014","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.clinre.2025.102591_bib0015","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2208450","article-title":"Vedolizumab for the treatment of chronic pouchitis","volume":"388","author":"Travis","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clinre.2025.102591_bib0017","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.clinre.2025.102591_bib0018","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clinre.2025.102591_bib0019","article-title":"Vedolizumab for induction and maintenance of remission in Crohn's disease","volume":"7","author":"Hui","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.clinre.2025.102591_bib0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinre.2025.102591_bib0021","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease in patients naive to or who have failed tumor necrosis factor antagonist therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clinre.2025.102591_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231159452","article-title":"Is there an optimal sequence of biologic therapies for inflammatory bowel disease?","volume":"16","author":"Bressler","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"issue":"8","key":"10.1016\/j.clinre.2025.102591_bib0025","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.clinre.2025.102591_bib0026","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.clinre.2025.102591_bib0027","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/ecco-jcc\/jjad043","article-title":"Effectiveness and safety of vedolizumab in inflammatory bowel disease: a comprehensive meta-analysis of observational studies","volume":"17","author":"Macaluso","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"9","key":"10.1016\/j.clinre.2025.102591_bib0028","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102591_bib0029","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ecco-jcc\/jjz137","article-title":"The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of global post-marketing data","volume":"14","author":"Cohen","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"10","key":"10.1016\/j.clinre.2025.102591_bib0030","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.clinre.2025.102591_bib0031","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13318-022-00804-6","article-title":"Pharmacokinetics and safety of vedolizumab following administration of a single intravenous dose in healthy Chinese subjects","volume":"48","author":"Xie","year":"2023","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.clinre.2025.102591_bib0032","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.clinre.2025.102591_bib0033","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clinre.2025.102591_bib0034","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clinre.2025.102591_bib0035","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cgh.2018.05.026","article-title":"Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases","volume":"17","author":"Feagan","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102591_bib0036","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/j.gastro.2019.06.038","article-title":"Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn's disease","volume":"157","author":"Danese","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clinre.2025.102591_bib0037","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Na\u00efve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.clinre.2025.102591_bib0038","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","article-title":"Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists","volume":"15","author":"Feagan","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.clinre.2025.102591_bib0039","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.cgh.2019.04.040","article-title":"Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases?","volume":"17","author":"Dulai","year":"2019","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"6","key":"10.1016\/j.clinre.2025.102591_bib0040","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.clnu.2024.04.013","article-title":"Real-world evidence of combined treatment of biologics and exclusive enteral nutrition in patients with ileum-dominant Crohn's disease: a multicenter study","volume":"43","author":"Wang","year":"2024","journal-title":"Clinical Nutrition"},{"issue":"3","key":"10.1016\/j.clinre.2025.102591_bib0041","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","article-title":"Defining disease severity in inflammatory bowel diseases: current and future directions","volume":"14","author":"Peyrin-Biroulet","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.clinre.2025.102591_bib0042","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.cgh.2008.06.010","article-title":"Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease","volume":"6","author":"Jones","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.clinre.2025.102591_bib0043","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3109\/00365521.2011.584897","article-title":"Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers","volume":"46","author":"Ricanek","year":"2011","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102591_bib0044","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212989","article-title":"Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"14","author":"Motoya","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.clinre.2025.102591_bib0045","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1007\/s12325-023-02500-6","article-title":"Safety and effectiveness of vedolizumab in patients with moderate-to-severe ulcerative colitis: an interim analysis of a Japanese post-marketing surveillance study","volume":"40","author":"Matsuoka","year":"2023","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.clinre.2025.102591_bib0046","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/jcph.1307","article-title":"A phase 1, multiple-dose study of vedolizumab in Japanese patients with ulcerative colitis","volume":"59","author":"Kobayashi","year":"2019","journal-title":"J Clin Pharmacol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125000713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125000713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:39:02Z","timestamp":1762601942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740125000713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2210740125000713"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102591","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of intravenous vedolizumab treatment in Chinese patients with moderate-to-severe Crohn's disease","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Takeda Development Centre Americas, Inc. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102591"}}